Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 375 participants.

Also called NCT06272487

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 375 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06272487
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Canada, Puerto Rico, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06272487. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-29 (actual); primary completion 2025-06-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Acronym
KARDIA-3
Condition
High Cardiovascular Risk
Condition
Hypertension
Intervention (Drug)
Zilebesiran
Intervention (Drug)
Placebo
Lead sponsor
Alnylam Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06272487
Content hash
9e370ffa6cb0522a9d89a207cb476fa37996cfd9edfb71417d3268b55281925f